Trials / Completed
CompletedNCT00406588
SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of SLV308 as Adjunct Therapy to Levodopa in Patients With Parkinson's Disease Experiencing Motor Fluctuations.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 295 (actual)
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multicenter, randomized, double blind, parallel group study of 3 months' treatment with SLV308 administered as a monotherapy in patients with advance stage PD. An open label safety extension to this study is planned as a separate protocol for patients who are willing and eligible to participate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levodopa (Pardoprunox) | 12-42mg |
| DRUG | Placebo Comparator | Placebo |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2008-04-01
- Completion
- 2008-05-01
- First posted
- 2006-12-04
- Last updated
- 2015-02-27
Locations
87 sites across 12 countries: United States, Argentina, Brazil, Bulgaria, Canada, Chile, Colombia, Latvia, Lithuania, Peru, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00406588. Inclusion in this directory is not an endorsement.